Page last updated: 2024-09-05

lixivaptan and nps-568

lixivaptan has been researched along with nps-568 in 1 studies

Compound Research Comparison

Studies (lixivaptan)	Trials (lixivaptan)	Recent Studies (post-2010) (lixivaptan)	Studies (nps-568)	Trials (nps-568)	Recent Studies (post-2010) (nps-568)
80	10	26	162	4	54

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Di Mise, A; Pellegrini, L; Torres, VE; Valenti, G; Wang, X; Ye, H	1

Other Studies

1 other study(ies) available for lixivaptan and nps-568

Article	Year
Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:10 Topics: Animals; Benzamides; Cyclic AMP; Drug Therapy, Combination; Female; Male; Mice; Mice, Inbred C57BL; Phenethylamines; Polycystic Kidney, Autosomal Dominant; Propylamines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Receptors, Vasopressin	2021

Article

Year

Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:10

Topics: Animals; Benzamides; Cyclic AMP; Drug Therapy, Combination; Female; Male; Mice; Mice, Inbred C57BL; Phenethylamines; Polycystic Kidney, Autosomal Dominant; Propylamines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Receptors, Vasopressin

2021